source
- Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapyNovo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
- Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series AVenture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…